

VETTER PHARMA



Vetter Pharma is a leading global contract development and manufacturing organisation (CDMO) for the aseptic production of injectables (Figure 1). Since its founding in 1950 in Ravensburg (Germany) as a family-owned pharmacy,

Vetter has grown to over 6,300 skilled employees worldwide. The company operates commercial production sites in Ravensburg and Langenargen (Germany) and clinical production facilities in Rankweil (Austria) and Chicago (IL, US) to

supply patients worldwide with potentially life-saving drugs, as well as branch offices for Asia Pacific in Singapore, Japan, South Korea and China.

The company has international expertise working with regulatory authorities including the US FDA, EMA, PMDA (Japan) and RP (Germany). Vetter offers services for pharma and biotech firms of all sizes and locations and holds numerous patents, including technologies for protection against tampering and counterfeiting. Vetter's expertise ranges from lyophilisation (freeze-drying) to siliconisation and more.

Vetter's mission is to produce drugs that enhance patient safety, comfort and compliance by providing tailored solutions to meet their partners' specific market needs. The company has been carbon neutral at all its corporate sites since 2021.

A FOCUS ON ENSURING CUSTOMERS' SUCCESS

As a globally operating CDMO partner, Vetter produces aseptically prefilled syringes, cartridges, vials and dual-chamber systems (Figure 2). It is an independent company rooted in over 70 years of history.

"Vetter offers services for pharma and biotech firms of all sizes and locations and holds numerous patents, including technologies for protection against tampering and counterfeiting."



Figure 1: Vetter offers versatile single-source manufacturing services.



Figure 2: Vetter manufactures sterile injectables through a highly complex, controlled and precise process.



Figure 3: Vetter supports customers in identifying the right packaging strategies for their unique drug compounds.

“Vetter supports its customers from the initial phases of clinical drug product development and filling through to commercial manufacturing, device assembly, packaging and lifecycle management.”

Vetter does not manufacture its own drugs, instead focusing on providing highly skilled support and state-of-the-art manufacturing resources to pharma partners. Vetter supports its customers from the initial phases of clinical drug product development and filling through to commercial manufacturing, device assembly, packaging and lifecycle

management (Figure 3). More than 80% of the company’s active projects are biologics.

A RELIABLE, RESPONSIVE AND PROGRESSIVE PARTNER

Vetter’s portfolio of services includes dedicated resources for clinical development; commercial manufacturing, assembly and

packaging; and more. Vetter offers the following services:

- **Drug Product Development:** Support in navigating key decisions early in a product’s evolution with scalability, quality and efficiency in mind.
- **Aseptic Filling and Visual Inspection:** Comprehensive expertise in manufacturing injectable drug products and related visual inspection systems.
- **Device Assembly and Packaging:** Strategic, technical and packaging support for patient-friendly combination products.
- **Analytical Services:** Robust, customisable testing methods for drug products, including evaluation and quality verification.
- **Regulatory Support:** Support in achieving milestones related to regulatory compliance during clinical development, market authorisation and beyond.
- **Logistic Services:** Cutting-edge solutions that maximise efficiency, transparency and precision of vital supply chains.

Vetter Pharma International GmbH

Schützenstraße 87
88212 Ravensburg
Germany

T: +49 75 137 000
E: info@vetter-pharma.com (EU/APAC)
infous@vetter-pharma.com (US)

www.vetter-pharma.com



**SUSTAINABLY
PRINTED*
& SHIPPED****



* using Forest Stewardship Council® certified recycled paper, vegetable-based inks, biodegradable laminates and carbon balanced materials offset via the World Land Trust™ following ISO140001 processes.

** by DHL using GoGreen Plus carbon insetting of at least 30% through the use of Sustainable Aviation Fuel (SAF), a biofuel substitute for traditional jet fuel, produced from renewable sources. Mailed to individual readers outside the UK by DHL using GoGreen, which offsets 100% of CO₂ emissions.

Unlock the full potential of your injectable product



Partner with a leading global CDMO for aseptic fill & finish



For 40+ years, pharma and biotech companies around the world have relied on Vetter to put their parenteral medications on a path to success. We're proud to help advance your innovative therapy with flexible, robust, scalable processes and services that set our partnership apart:



- Specialized support for your unique clinical development program
- High-quality aseptic filling at both clinical and global commercial scale
- Strategic packaging and device assembly solutions that span your product's life cycle
- Comprehensive technical, analytical, and regulatory expertise at every step

Rely on us.

[in](#) [▶](#) [🐦](#) vetter-pharma.com

